As Time Goes By. Current Status and Future Directions in the Controversy Over Stenting

Journal of the American College of Cardiology

Volumn 50, Issue 2, 2007, Pages 128-137

  Kaul, Sanjay ^a   Shah, Prediman K ^a   Diamond, George A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; PACLITAXEL; RAPAMYCIN;

ANGIOGRAPHY; ANTICOAGULANT THERAPY; BLEEDING; CARDIOLOGY; CLINICAL PRACTICE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; EVIDENCE BASED MEDICINE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HUMAN; KINETICS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REIMBURSEMENT; RESTENOSIS; REVIEW; RISK ASSESSMENT; STENT; THROMBOSIS;

CORONARY DISEASE; CORONARY RESTENOSIS; CORONARY THROMBOSIS; DRUG DELIVERY SYSTEMS; HUMANS; MODELS, CARDIOVASCULAR; PLATELET AGGREGATION INHIBITORS; PRODUCT LABELING; PROSTHESIS DESIGN; REIMBURSEMENT MECHANISMS; RISK FACTORS; STENTS; UNITED STATES;

EID: 34347260658     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.04.030     Document Type: Review

References (45)

1. Lyrics and music by Herman Hupfield; ©1931 Warner Bros. Music Corp., ASCAP. Available at: http://www.cyberblanca.com/lyrics.html. Accessed May 10, 2007.
2. Tung R., Kaul S., Diamond G.A., and Shah P.K. Narrative review: drug-eluting stents for the management of restenosis: a critical appraisal of the evidence. Ann Intern Med 144 (2006) 913-919
3. Yock A., Isbill J.M., and King III S.B. Bare-metal stent outcomes in an unselected patient population. Clin Cardiol 29 (2006) 352-356
4. Kaiser C., Brunner-LaRocca H.P., Buser P.T., et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitäts Trial (BASKET). Lancet 366 (2005) 921-929
5. Instructions for Use: CYPHER™ Sirolimus-eluting Coronary Stent on RAPTOR™ Over-the-Wire Delivery System and CYPHER™ Sirolimus-eluting Coronary Stent RAPTORRAIL® Rapid Exchange Delivery System. Available at: http://www.fda.gov/cdrh/PDF2/p020026c.pdf. Accessed May 10, 2007.
6. 2™ Paclitaxel-Eluting Coronary Stent System. Available at: http://www.fda.gov/cdrh/PDF3/P030025c.pdf. Accessed May 10, 2007.
7. Iakovou I., Schmidt T., Bonizzoni E., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 (2005) 2126-2130
8. Kuchulakanti PK Chu W.W., Torguson R., et al. Correlates and long-term outcomes of angiographically proven stent thrombosis of sirolimus- and paclitaxel-eluting stents. Circulation 113 (2006) 1108-1113
9. DeMaria A.N., Ben-Yehuda O., Feld G.K., et al. Highlights of the year in JACC 2006. J Am Coll Cardiol 49 (2007) 509-527
10. Pfisterer M.E., Brunner-La Rocca H.P., Buser P.T., et al., BASKET-LATE Investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting stents versus bare-metal stents. J Am Coll Cardiol 48 (2006) 2584-2591
11. Bavry A.A., Kumbhani D.J., Helton T.J., Borek P.P., Mood G.R., and Bhatt D.L. Late thrombosis of drug-eluting stent: a meta-analysis of randomized clinical trials. Am J Med 119 (2006) 1056-1061
12. Stone G.W., Moses J.W., Ellis S.G., et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356 (2007) 998-1008
13. Daemen J., Wenaweser P., Tsuchida K., et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369 (2007) 667-678
14. Cutlip DE, Baim DS, Ho KKL, et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 103:1967-71.
15. Heller L., Shemwell K.C., and Hug K. Late stent thrombosis in the absence of prior intracoronary brachytherapy. Catheter Cardiovasc Interv 53 (2001) 23-28
16. Ong A.T.L., McFadden E.P., Regar E., de Jaegere P.P.T., van Domburg R.T., and Serruys P.W. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 45: (2005) 2088-2092
17. Mauri L., Hsieh W.H., Massaro J.M., Ho K.K., D'Agostino R., and Cutlip D.E. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356 (2007) 1020-1029
18. Smith Jr. S.C., Feldman T.E., Hirshfeld Jr. J.W., et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 47 (2006) 216-235
19. Spertus J.A., Kettelkamp R., Vance C., et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 113 (2006) 2803-2809
20. Bhatt D.L., Fox K.A., Hacke W., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354 (2006) 1706-1717
21. Camenzind E., Gabriel Steg P., and Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation 115 (2007) 1440-1455 discussion 1455
22. Nordmann A.J., Briel M., and Bucher H.C. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J 27 (2006) 2784-2814
23. Wijns W.C., and Krucoff M.W. Increased mortality after implantation of first generation drug-eluting stents: seeing the smoke, where is the fire?. Eur Heart J 27 (2006) 2737-2739
24. RAVEL: Five-year outcomes. Presented by Morice M-C, Serruys PW. European Society of Cardiology Scientific Congress, September 2006. Available at: http://www.escardio.org/knowledge/congresses/CongressReports/hotlinesandctus/710007_Morice.htm. Accessed January 28, 2007.
25. Diamond G.A., and Kaul S. Prior convictions: Bayesian approaches to the analysis and interpretation of clinical megatrials. J Am Coll Cardiol 43 (2004) 1929-1939
26. Update to FDA Statement on Coronary Drug-Eluting Stents. Available at: http://www.fda.gov/cdrh/news/010407.html. Accessed January 28, 2007.
27. Smith SC Jr., Feldman TE, Hirshfeld JW Jr., et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). American College of Cardiology Web Site. Available at: http://www.acc.org/clinical/guidelines/percutaneous/update/index.pdf. Accessed on May 10, 2007.
28. Kastrati A., Mehilli J., Pache J., et al. Analysis of 14 trials comparing sirolimus-eluting stents versus bare-metal stents. New Engl J Med 356 (2007) 1030-1039
29. Spaulding C., Daemen J., Boersma E., Cutlip D.E., and Serruys P.W. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 989-997
30. Lagerqvist B., James S.K., Stenestrand U., Lindback J., Nilsson T., and Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356 (2007) 1009-1019
31. Baim D.S. Real-world use of the TAXUS Drug-eluting Stent System (2007). http://www.taxus-stent.com/usa/hcp_fda_info.html Available at: http://www.taxus-stent.com/usa/hcp_fda_info.html. Accessed January 28
32. Eisenstein E.L., Anstrom K.J., Kong D.F., et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 297 (2007) 159-168
33. Colombo A. Incidence and Predictions of Drug Eluting Stent Thrombosis during and Following Discontinuation of Thienopyrdine Treatment. Available at: http://www.fda.gov/ohrms/dockets/ac/06/slides/2006-4253oph1_06_Colombo.pdf. Accessed January 28, 2007.
34. Grines C.L., Bonow R.O., Casey Jr. D.E., et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents. Circulation 115 (2007) 813-818
35. Kaul S, Diamond GA. Drug-Eluting Stents: Balancing Benefits and Risks. Available at: http://www.fda.gov/ohrms/dockets/AC/06/slides/2006-4253oph2_09_Kaul.pdf. Accessed January 28, 2007.
36. Katritsis D.G., and Ioannidis J.P. Percutaneous coronary intervention versus conservative therapy in nonacute coronary artery disease: a meta-analysis. Circulation 111 (2005) 2906-2912
37. Boden W.E., O'Rourke R.A., Teo K.K., et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356 (2007) 1503-1516
38. Laarman G.J., Suttorp M.J., Dirksen M.T., et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 355 (2006) 1105-1113
39. Spaulding C., Henry P., Teiger E., et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 355 (2006) 1093-1104
40. Diamond G.A., and Kaul S. From here to eternity. A unified kinetic model for the pathophysiology of atherosclerotic events. Am J Med 120 (2007) 5-11
41. Gillespie D.T. A general method for numerically simulating the stochastic time evolution of coupled chemical reactions. J Comput Phys 22 (1976) 403
42. Hall R.F., and Sobotka E.S. Inconsistent government policies: how FDA off-label regulation cannot survive First Amendment review under Greater New Orleans. Food Drug Law J 62 (2007) 1-48
43. Diamond G.A., Denton T.A., and Matloff J.M. Fee-for-benefit. A strategy to improve the quality of health care and control costs through reimbursement incentives. J Am Coll Cardiol 22 (1993) 343-352
44. National Coverage Determination process for CMS (2007). http://www.cms.hhs.gov/DeterminationProcess/ Available at: http://www.cms.hhs.gov/DeterminationProcess/. Accessed February 6
45. Epstein A.M. Pay for performance at the tipping point. N Engl J Med 356 (2007) 515-517